Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia

Sickle Cell Disease Clinical Trial

— CVR  

Official title:

Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03715972
• Other study ID #: 17-00496
• Secondary ID: 1R01HL136484-01A
• Status: Completed
• Start date: July 15, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: May 2023
• Source: Children's Hospital Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is primarily an observational trial in patients with chronic anemia syndromes (sickle cell disease and thalassemia) and control subjects. The key purpose is to understand how brain blood flow reserve (the ability of the brain to increase its flow in response to stress) is altered in patients with chronic anemia. Since this parameter may depend on anemia severity, we will perform the MRI monitoring prior to and following clinically indicated transfusions in a subset of patients. Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose. The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients as well as 40 control subjects recruited from first degree relatives of the sickle cell disease population. All eligible subjects will be asked to provide informed consent before participating in the study.

Description:

This is primarily an observational trial in patients with chronic anemia syndromes (sickle cell disease and thalassemia) and control subjects. The key purpose is to understand how brain blood flow reserve (the ability of the brain to increase its flow in response to stress) is altered in patients with chronic anemia. Since this parameter may depend on anemia severity, we will perform the MRI monitoring prior to and following clinically indicated transfusions in a subset of patients. Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose. The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients as well as 40 control subjects recruited from first degree relatives of the sickle cell disease population. All eligible subjects will be asked to provide informed consent before participating in the study.

Treatment:

All patients will undergo baseline phlebotomy, brain MRI, and neurocognitive testing. The MRI will include measurements of brain blood flow prior to and following administration of 16 mg/kg of acetazolamide to maximally vasodilate the cerebral vasculature. All transfusion dependent patients will have their MRI performed immediately prior to a routinely scheduled transfusion at their hemoglobin nadir. 20 sickle cell disease patients on chronic simple transfusions and 10 thalassemia patients on chronic simple transfusions will undergo repeat MRI assessment of cerebral blood flow and reactivity following their clinically indicated blood transfusion. 10 sickle cell disease patients on exchange transfusions will undergo repeat MRI assessment of cerebral blood flow and reactivity following their clinically indicated exchange transfusion; this transfusion will be performed to lower their hemoglobin S percentage by 25% points while keeping the total hemoglobin unchanged (isocrit exchange). 20 non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop.

Safety Assessment:

All patients will have a physician present during the MRI examination to monitor vital signs and response to acetazolamide. Patients placed onto hydroxyurea will have monthly study visits with monitoring of complete blood count, vital signs, complete metabolic panel, and hemoglobin electrophoresis. Adverse events will be assessed at every study visit after the first dose through to the last subject visit.

Efficacy Assessments:

Baseline cerebrovascular reserve (CVR) predictors will be assessed by multivariate regression after appropriate transformations. Potential independent predictors include oxygen content, hemoglobin subtype, as well as markers of hemolysis, inflammation, and iron overload.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 165
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 7 Years and older

Eligibility

• Inclusion Criteria:

1. Diagnosis of sickle cell disease (genotype SS, SC, or SB0), thalassemia (transfusion dependent or transfusion independent), or normal control subject that are =18yrs, ethnicity, and sex matched to the sickle cell disease population.

2. Ability to tolerate a one hour MRI examination.

3. Age equal to or greater than 7 years old for Anemia groups.

4. Agreeable to use an approved method of contraception for the entire duration of hydroxyurea usage if accepted onto the hydroxyurea substudy (male or female of childbearing potential)

Exclusion Criteria:

1. Hospitalization within one month

2. Contraindication to acetazolamide use (seizures)

3. Severe claustrophobia.

4. Pregnancy or nursing (a negative HCG (pregnancy) test must be obtained prior to MRI)

5. As a result of medical review, physical examination or screening investigations, the Principal Investigator (PI) considers the subject unfit for the study

6. No fixed address

7. In control subjects, chronic hepatitis, diabetes, hypertension, coronary artery disease, cognitively impaired or developmental delay

Related Conditions & MeSH terms

• Anemia
• Anemia, Sickle Cell
• Healthy Controls
• Leukoencephalopathies
• Sickle Cell Disease
• Thalassemia

Intervention

Drug:
• Hydroxyurea
info included in arm group
• Acetazolamide
Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.

Locations

Country	Name	City	State
United States	CHLA	Los Angeles	California

Sponsors (4)

Lead Sponsor	Collaborator
Children's Hospital Los Angeles	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CVR response to transfusion	Cerebral vascular flow reserve will be assessed prior to and following a regularly scheduled blood transfusion	3-5 days
Primary	CVR response to hydroxyurea therapy	Change in cerebral vascular reserve at baseline and after initiation of hydroxyurea titrated to maximum tolerated dose	2-4 months
Secondary	Predictors of CVR response	We will determine what factors determine cerebral blood flow response to diamox vasodilator challenge	Single study visit